Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Mar 15, 2025; 17(3): 102873
Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.102873
Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.102873
Table 3 Comparison of adverse reaction incidence, n (%)
Adverse reaction | Control (n = 21) | Observation (n = 22) | χ2 | P value |
Nausea and vomiting | 8 (38.10) | 6 (27.27) | 0.573 | 0.449 |
Gastrointestinal reaction | 5 (23.81) | 4 (18.18) | 0.006 | 0.937 |
Skin reaction | 3 (14.29) | 4 (18.18) | 0.004 | 0.946 |
Bone marrow suppression | 4 (19.05) | 5 (22.73) | 0.006 | 0.937 |
Liver and kidney function damage | 13 (61.90) | 11 (50.00) | 0.617 | 0.432 |
Neurotoxicity | 2 (9.52) | 4 (18.18) | 0.143 | 0.704 |
Leukopenia | 8 (38.10) | 7 (31.82) | 0.186 | 0.665 |
Neutropenia | 5 (23.81) | 6 (27.27) | 0.067 | 0.794 |
Thrombocytopenia | 6 (28.57) | 7 (31.82) | 0.053 | 0.816 |
- Citation: Ni J, Wan CG, Sui ZQ. Efficacy and safety of radiotherapy in patients with microsatellite stable or proficient mismatch repair colorectal cancer liver metastasis. World J Gastrointest Oncol 2025; 17(3): 102873
- URL: https://www.wjgnet.com/1948-5204/full/v17/i3/102873.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i3.102873